Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to Imatinib Mesylate in BCR-ABL positive acute lymphoblastic leukemia

Leuk Res. 2009 Jul;33(7):e73-4. doi: 10.1016/j.leukres.2008.11.009. Epub 2008 Dec 23.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Benzamides
  • Drug Resistance, Neoplasm*
  • Fusion Proteins, bcr-abl / genetics
  • Fusion Proteins, bcr-abl / metabolism*
  • Humans
  • Imatinib Mesylate
  • Male
  • Philadelphia Chromosome
  • Piperazines / therapeutic use*
  • Point Mutation / genetics*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics*
  • Proto-Oncogene Proteins c-abl / genetics*
  • Pyrimidines / therapeutic use*

Substances

  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl
  • Proto-Oncogene Proteins c-abl